The Journal of Immunology, Vol 151, Issue 8 4209-4220, Copyright © 1993 by American Association of Immunologists

ARTICLES

Tumor-specific lysis of human renal cell carcinomas by tumor- infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines

DJ Schendel, B Gansbacher, R Oberneder, M Kriegmair, A Hofstetter, G Riethmuller and OG Segurado
Institut fur Immunologie, Ludwig-Maximilians-Universitat Munchen, Germany.

Metastatic renal cell carcinoma (RCC), like melanoma, belongs to the small group of human tumors in which partial or complete remission has been observed in some patients after treatment with various forms of immunotherapy. In contrast to melanoma, CTL showing MHC-restricted lysis of RCC have not been easily found among tumor-infiltrating lymphocytes (TIL). This has led to the suggestion by some that responses to immunotherapy are mediated predominantly by non-MHC- restricted effector cells. We have characterized an MHC-restricted, CD8+ CTL line obtained from an uncloned TIL population of a primary RCC using a low concentration of rIL-2; in fact, these CTL represented a majority of the short-term cultured TIL population. The CTL lysed autologous tumor cells but not normal kidney cells or target cells sensitive to non-MHC-restricted effector cells. In contrast, lymphokine- activated killer (LAK) cells grown in a high concentration of rIL-2 from the patient's PBL lysed autologous tumor and normal kidney cells in addition to several allogeneic tumors. The TIL could be expanded optimally using an autologous tumor line retrovirally transduced with the human cDNA encoding IL-2. TIL were 20-fold more potent than LAK cells in eliminating the IL-2 expressing tumor cells in vitro. The cultured TIL utilized a restricted number of V alpha gene families, suggesting that they may recognize only a limited number of MHC-peptide complexes presented by autologous tumor cells. HLA-A2 was identified as an MHC restriction molecule for presentation of one tumor-derived peptide to these CTL. Only some allogeneic HLA-A2 RCC tumors were lysed. Sequencing of the second and third exons of the HLA-A2 alleles of these cells revealed that both heterogeneity in MHC and peptide availability influenced CTL recognition. These studies demonstrate that some RCC express common antigenic determinants that can be recognized by MHC-restricted CTL and open the possibility of defining the nature of RCC-derived peptides, which, combined with HLA-A2, can generate specific immune responses.

This article has been cited by other articles:

				R. Riesenberg, C. Weiler, O. Spring, M. Eder, A. Buchner, T. Popp, M. Castro, R. Kammerer, O. Takikawa, R. A. Hatz, et al. Expression of Indoleamine 2,3-Dioxygenase in Tumor Endothelial Cells Correlates with Long-term Survival of Patients with Renal Cell Carcinoma Clin. Cancer Res., December 1, 2007; 13(23): 6993 - 7002. [Abstract] [Full Text] [PDF]

				Q.-S. Du, Y.-T. Wei, Z.-W. Pang, K.-C. Chou, and R.-B. Huang Predicting the affinity of epitope-peptides with class I MHC molecule HLA-A*0201: an application of amino acid-based peptide prediction Protein Eng. Des. Sel., September 1, 2007; 20(9): 417 - 423. [Abstract] [Full Text] [PDF]

				S. Kausche, T. Wehler, E. Schnurer, V. Lennerz, W. Brenner, S. Melchior, M. Grone, M. Nonn, S. Strand, R. Meyer, et al. Superior Antitumor In vitro Responses of Allogeneic Matched Sibling Compared with Autologous Patient CD8+ T Cells Cancer Res., December 1, 2006; 66(23): 11447 - 11454. [Abstract] [Full Text] [PDF]

				V. Milani, B. Frankenberger, O. Heinz, A. Brandl, S. Ruhland, R. D. Issels, and E. Noessner Melanoma-associated antigen tyrosinase but not Melan-A/MART-1 expression and presentation dissociate during the heat shock response Int. Immunol., March 1, 2005; 17(3): 257 - 268. [Abstract] [Full Text] [PDF]

				B. Frankenberger, H. Pohla, E. Noessner, G. Willimsky, B. Papier, A. Pezzutto, J. Kopp, R. Oberneder, T. Blankenstein, and D. J. Schendel Influence of CD80, Interleukin-2, and Interleukin-7 Expression in Human Renal Cell Carcinoma on the Expansion, Function, and Survival of Tumor-Specific CTLs Clin. Cancer Res., March 1, 2005; 11(5): 1733 - 1742. [Abstract] [Full Text] [PDF]

				A. Dorrschuck, A. Schmidt, E. Schnurer, M. Gluckmann, C. Albrecht, C. Wolfel, V. Lennerz, A. Lifke, C. Di Natale, E. Ranieri, et al. CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression Blood, October 15, 2004; 104(8): 2591 - 2599. [Abstract] [Full Text] [PDF]

				P. Rayman, A. K. Wesa, A. L. Richmond, T. Das, K. Biswas, G. Raval, W. J. Storkus, C. Tannenbaum, A. Novick, R. Bukowski, et al. Effect of Renal Cell Carcinomas on the Development of Type 1 T-Cell Responses Clin. Cancer Res., September 15, 2004; 10(18): 6360S - 6366S. [Abstract] [Full Text] [PDF]

				C. S. Falk, E. Noessner, E. H. Weiss, and D. J. Schendel Retaliation against Tumor Cells Showing Aberrant HLA Expression Using Lymphokine Activated Killer-derived T Cells Cancer Res., January 1, 2002; 62(2): 480 - 487. [Abstract] [Full Text] [PDF]

				S. S. Joshi, J. C. Lynch, S. Z. Pavletic, S. R. Tarantolo, S. J. Pirruccello, A. Kessinger, and M. R. Bishop Decreased immune functions of blood cells following mobilization with granulocyte colony-stimulating factor: association with donor characteristics Blood, September 15, 2001; 98(6): 1963 - 1970. [Abstract] [Full Text] [PDF]

				C. Menetrier-Caux, M. C. Thomachot, L. Alberti, G. Montmain, and J. Y. Blay IL-4 Prevents the Blockade of Dendritic Cell Differentiation Induced by Tumor Cells Cancer Res., April 1, 2001; 61(7): 3096 - 3104. [Abstract] [Full Text]

				J. L. M. Vissers, I. J. M. De Vries, M. W. J. Schreurs, L. P. H. Engelen, E. Oosterwijk, C. G. Figdor, and G. J. Adema The Renal Cell Carcinoma-associated Antigen G250 Encodes a Human Leukocyte Antigen (HLA)-A2.1-restricted Epitope Recognized by Cytotoxic T Lymphocytes Cancer Res., November 1, 1999; 59(21): 5554 - 5559. [Abstract] [Full Text] [PDF]

				S. Osanto Vaccine Trials for the Clinician: Prospects for Tumor Antigens Oncologist, October 1, 1997; 2(5): 284 - 299. [Abstract] [Full Text] [PDF]